The Assessment of Prednisone In Remission Trial (TAPIR)

Status Active, not recruiting

Clinical Trial Summary

This is a randomized controlled trial in patients with a diagnosis of granulomatosis with polyangiitis (GPA; Wegener's)that are in remission to evaluate the effects of using low-dose glucocorticoids ( 5 mg/day of prednisone) as compared to stopping glucocorticoid treatment entirely (0 mg/day of prednisone)on rates of disease relapse/disease flares. This study is a novel approach to conducting a randomized clinical trial in the community setting. This study is being conducted in parallel with a similar study at established vasculitis institutions. This study will have a patient centric approach to research in that subjects will be recruited online and through social media and vasculitis support networks. Participants will be consented online and will receive care through their regular treating physician so no travel or additional doctor visits are required. Study participants will consent to the study and complete online questionnaires about their prednisone dose and about how they are feeling.

Clinical Trial Description

This open label pilot study will randomize 60 participants with GPA in remission affecting the sinonasal tract, oral mucosa, skin, musculoskeletal system, pulmonary parenchyma, or other disease features that warranted an administration of 20 mg/day or more within the last 12 months. At the time of enrollment, participants will need to be taking prednisone at a dose of ≥ 5mg/day and ≤ 20 mg/day. All enrolled participants will be instructed to reduce the daily dose of prednisone according to their treating physician. Once participants reach a prednisone dose of 5mg/day, they will be randomized at a 1:1 ratio to continue prednisone at 5 mg/day or to taper prednisone to 0 mg/day. Participants will be followed for approximately six months from reaching a prednisone dose of 5 mg/day. The primary study outcome is the proportion of participants who increase prednisone for disease relapse within 6 months of randomization. Participant data collected via this study will be combined with that from a complementary study conducted at Vasculitis Clinical Research Consortium (VCRC) clinical centers. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01933724
Study type	Interventional
Source	University of South Florida
Contact
Status	Active, not recruiting
Phase	Phase 3
Start date	February 17, 2014
Completion date	December 31, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT02498808` - Interferon-lambda: Novel Biologics for Controlling Neutrophil-mediated Pathology in Rheumatic Diseases?	N/A
Completed	`NCT01363388` - A Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With ANCA-Associated Vasculitis	Phase 2
Completed	`NCT00004357` - Absorption of Corticosteroids in Children With Juvenile Dermatomyositis	Phase 2
Recruiting	`NCT05263817` - A Clinical Study of CD19/BCMA CAR-T Cells in the Treatment of Refractory POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, and Vasculitis	Early Phase 1
Recruiting	`NCT05635266` - Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Completed	`NCT01947465` - Immunogenicity and Safety of Vaccinations in Immunocompromised Persons	N/A
Completed	`NCT02240888` - Vaccination in Inflammatory Rheumatic Disease (VACCIMIL). The Impact of Antirheumatic Treatment on Antibody Response	N/A
Completed	`NCT03693586` - Study to Determine the Hepatitis C Virus Infection Prevalence Among Patients Attended Primarily for Vasculitis
Completed	`NCT05604482` - CXCR4-PET/CT for Diagnosing Giant Cell Arteritis	N/A
Completed	`NCT03765424` - Evaluation of Ultrasound and PET/CT in the Diagnosis and Monitoring of Giant Cell Arteritis
Recruiting	`NCT06065852` - National Registry of Rare Kidney Diseases
Recruiting	`NCT05383339` - Biomarkers in Autoimmune Diseases, Vasculitis and Auto Inflammatory Diseases
Active, not recruiting	`NCT03755245` - Biodistribution, Dosimetry and Performance of [68Ga]Ga-DOTA-Siglec-9 in Healthy and Patients With Rheumatoid Arthritis, Vasculitis or Pulmonary Sarcoidosis	N/A
Recruiting	`NCT05565885` - Search for BIO Diagnostic and Prognostic Markers in Adult VAScularitis
Recruiting	`NCT02593565` - Vasculitis Pregnancy Registry
Recruiting	`NCT02856243` - Direct Antiviral Agents for Hepatitis C Virus-associated Cryoglobulinaemia Vasculitis	N/A
Recruiting	`NCT05628948` - Vascular Lab Resource (VLR) Biorepository
Active, not recruiting	`NCT03692416` - The Effect of Some Drugs Used in Treatment of Vasculitis on the Complement System in Children	Phase 3
Completed	`NCT05115370` - Vaccination Perception in Inflammatory Conditions - Flu, Pneumonia and COVID-19
Terminated	`NCT03937856` - Smartphone Mindfulness Meditation for Patients With Rheumatic Diseases	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

The Assessment of Prednisone In Remission Trial (TAPIR) - Patient Centric Approach — TAPIR

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms